Skip to main content
Clinical Trials/TCTR20201020001
TCTR20201020001
Completed
Phase 1

Phase I clinical trial to evaluate safety, pharmacokinetics and immunomodulatory activity of the capsule formulation of the standardized extract of Atractylodes lancea

ational Research Council of Thailand0 sites48 target enrollmentOctober 20, 2020

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
one.
Sponsor
ational Research Council of Thailand
Enrollment
48
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 20, 2020
End Date
June 10, 2019
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
ational Research Council of Thailand

Eligibility Criteria

Inclusion Criteria

  • non\-smokers and non\-alcohol drinkers and were residents of Bangkok or suburb areas were recruited into the study. Additional inclusion criteria were (i) absence of acute or chronic diseases that could affect vital organ functions, (ii) no history of surgery within the past six months, (ii) no history of hypersensitivity reactions or idiosyncratic reactions to drugs or herbal products, (iv) no concurrent or history of administration of drugs or herbal products within the past two weeks (except antipyretic or anti\-emetic drugs), (v) no history or current drug abuse, (vi) ability to communicate (reading, writing, and speaking) effectively, and (vii) willing to give informed consent for study participation.

Exclusion Criteria

  • with (i) clinical significant abnormality of physical examination, (ii) clinical significant abnormality of electrocardiograms (ECG) or chest x\-ray, (iii) pregnancy or lactation, (iv) blood tests positive for HBsAg, HCV, or HIV, (v) abnormality in blood coagulation or history or concurrent use of anticoagulants or antiplatelets, or (vi) participation in any other study in the past three months.

Outcomes

Primary Outcomes

Not specified

Similar Trials